Published in Transplantation on January 01, 2016
Protecting the Kidney in Liver Transplant Recipients: Practice-Based Recommendations From the American Society of Transplantation Liver and Intestine Community of Practice. Am J Transplant (2016) 0.77
Infection-related hospitalizations after kidney transplantation in children: incidence, risk factors, and cost. Pediatr Nephrol (2017) 0.75
Rabbit anti-human thymocyte immunoglobulin for the rescue treatment of chronic antibody-mediated rejection after pediatric kidney transplantation. Pediatr Nephrol (2017) 0.75
Impact of the Trough Level of Calcineurin Inhibitor on the Prevalence of Donor-Specific Human Leukocyte Antigen Antibodies During Long-Term Follow-Up After Pediatric Liver Transplantation: Antibody Strength and Complement-Binding Ability. Transplant Direct (2017) 0.75
Complement-binding anti-HLA antibodies and kidney-allograft survival. N Engl J Med (2013) 6.31
A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant (2010) 5.40
Banff '05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN'). Am J Transplant (2007) 5.39
Rabbit antithymocyte globulin versus basiliximab in renal transplantation. N Engl J Med (2006) 4.79
Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Engl J Med (2008) 4.32
Alemtuzumab induction in renal transplantation. N Engl J Med (2011) 4.13
Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence. Am J Transplant (2011) 4.06
Alemtuzumab-based induction treatment versus basiliximab-based induction treatment in kidney transplantation (the 3C Study): a randomised trial. Lancet (2014) 4.05
Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties. Am J Transplant (2005) 4.05
A case for regulatory B cells. J Immunol (2006) 3.20
A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study). Am J Transplant (2010) 3.05
Rapamune (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. Clin Biochem (1998) 2.85
Campath-1H induction plus rapamycin monotherapy for renal transplantation: results of a pilot study. Am J Transplant (2003) 2.83
SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo. Transplantation (1997) 2.80
B-cell-depleting induction therapy and acute cellular rejection. N Engl J Med (2009) 2.56
Consensus guidelines on the testing and clinical management issues associated with HLA and non-HLA antibodies in transplantation. Transplantation (2013) 2.55
Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant. Am J Transplant (2012) 2.46
Daclizumab versus antithymocyte globulin in high-immunological-risk renal transplant recipients. J Am Soc Nephrol (2009) 2.08
Crossmatch-positive liver transplantation in patients receiving thymoglobulin-rituximab induction. Transplantation (2014) 2.00
Donor-specific HLA antibodies: risk factors and outcomes after kidney transplantation. Transplant Proc (2011) 1.99
An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib. Br J Haematol (2012) 1.94
Three-year outcomes from BENEFIT, a randomized, active-controlled, parallel-group study in adult kidney transplant recipients. Am J Transplant (2011) 1.93
Donor-specific HLA antibodies in a cohort comparing everolimus with cyclosporine after kidney transplantation. Am J Transplant (2012) 1.78
Class II HLA epitope matching-A strategy to minimize de novo donor-specific antibody development and improve outcomes. Am J Transplant (2013) 1.77
Regulatory T cells and T cell depletion: role of immunosuppressive drugs. J Am Soc Nephrol (2007) 1.75
Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection. Transplantation (2008) 1.66
Deleterious effect of CTLA4-Ig on a Treg-dependent transplant model. Am J Transplant (2012) 1.61
A closer look at rituximab induction on HLA antibody rebound following HLA-incompatible kidney transplantation. Kidney Int (2014) 1.56
"Plasma cell hepatitis" in liver allografts: identification and characterization of an IgG4-rich cohort. Am J Transplant (2013) 1.52
Neither pre-transplant rituximab nor splenectomy affects de novo HLA antibody production after renal transplantation. Kidney Int (2013) 1.51
Belatacept-based immunosuppression in de novo liver transplant recipients: 1-year experience from a phase II randomized study. Am J Transplant (2014) 1.50
Experience with a novel efalizumab-based immunosuppressive regimen to facilitate single donor islet cell transplantation. Am J Transplant (2010) 1.48
Inhibition of T and B lymphocyte proliferation by rapamycin. Immunology (1991) 1.48
Rituximab as induction therapy after renal transplantation: a randomized, double-blind, placebo-controlled study of efficacy and safety. Am J Transplant (2015) 1.47
C1q-fixing human leukocyte antigen antibodies are specific for predicting transplant glomerulopathy and late graft failure after kidney transplantation. Transplantation (2011) 1.43
Extremely high association between appearance of HLA antibodies and failure of kidney grafts in a five-year longitudinal study. Am J Transplant (2007) 1.43
Predictive factors of allosensitization in renal transplant patients switched from calcineurin to mTOR inhibitors. Transpl Int (2014) 1.43
The BAFF/APRIL system in SLE pathogenesis. Nat Rev Rheumatol (2014) 1.37
Frequency and clinical implications of development of donor-specific and non-donor-specific HLA antibodies after kidney transplantation. J Am Soc Nephrol (2005) 1.36
Incidence and impact of de novo donor-specific alloantibody in primary renal allografts. Transplantation (2013) 1.33
The BAFF/APRIL system: emerging functions beyond B cell biology and autoimmunity. Cytokine Growth Factor Rev (2013) 1.31
HLA class I antibody-mediated endothelial cell proliferation via the mTOR pathway. J Immunol (2008) 1.31
Belatacept-based regimens versus a cyclosporine A-based regimen in kidney transplant recipients: 2-year results from the BENEFIT and BENEFIT-EXT studies. Transplantation (2010) 1.28
De novo DQ donor-specific antibodies are associated with a significant risk of antibody-mediated rejection and transplant glomerulopathy. Transplantation (2012) 1.28
Inhibition of human B lymphocyte cell cycle progression and differentiation by rapamycin. Cell Immunol (1994) 1.26
Proteasome inhibitor-based primary therapy for antibody-mediated renal allograft rejection. Transplantation (2010) 1.25
HLA-specific antibodies developed in the first year posttransplant are predictive of chronic rejection and renal graft loss. Transplantation (2009) 1.23
De novo donor HLA-specific antibodies after heart transplantation are an independent predictor of poor patient survival. Am J Transplant (2011) 1.22
CD40-specific costimulation blockade enhances neonatal porcine islet survival in nonhuman primates. Am J Transplant (2011) 1.19
Sirolimus versus cyclosporine therapy increases circulating regulatory T cells, but does not protect renal transplant patients given alemtuzumab induction from chronic allograft injury. Transplantation (2007) 1.18
Chronic antibody-mediated rejection is reduced by targeting B-cell immunity during an introductory period. Am J Transplant (2011) 1.17
Effects of immunosuppressive drugs on purified human B cells: evidence supporting the use of MMF and rapamycin. Transplantation (2008) 1.17
Late antibody-mediated rejection in renal allografts: outcome after conventional and novel therapies. Transplantation (2014) 1.16
Emerging therapies targeting the ubiquitin proteasome system in cancer. J Clin Invest (2014) 1.13
The use of mycophenolate mofetil in transplant recipients. Immunopharmacology (2000) 1.13
Epratuzumab targeting of CD22 affects adhesion molecule expression and migration of B-cells in systemic lupus erythematosus. Arthritis Res Ther (2010) 1.12
T-lymphocyte alloresponses of Campath-1H-treated kidney transplant patients. Transplantation (2006) 1.12
Non-adherence to immunosuppressive medication in renal transplant recipients within the scope of the Integrative Model of Behavioral Prediction: a cross-sectional study. Clin Transplant (2009) 1.12
The role of immunoglobulin-G subclasses and C1q in de novo HLA-DQ donor-specific antibody kidney transplantation outcomes. Transplantation (2013) 1.11
Donor-specific HLA-DQ antibodies may contribute to poor graft outcome after renal transplantation. Kidney Int (2012) 1.09
Implications for human leukocyte antigen antibodies after lung transplantation: a 10-year experience in 441 patients. Chest (2013) 1.08
Multiple mechanisms of B cell immunoregulation in man after administration of in vivo corticosteroids. J Immunol (1984) 1.08
De novo donor-specific HLA antibodies decrease patient and graft survival in liver transplant recipients. Am J Transplant (2013) 1.07
Mesenchymal stem cells together with mycophenolate mofetil inhibit antigen presenting cell and T cell infiltration into allogeneic heart grafts. Transpl Immunol (2010) 1.04
Calcineurin inhibitors affect B cell antibody responses indirectly by interfering with T cell help. Clin Exp Immunol (2009) 1.04
Prevalence, course and impact of HLA donor-specific antibodies in liver transplantation in the first year. Am J Transplant (2012) 1.04
Advances and challenges in immunotherapy for solid organ and hematopoietic stem cell transplantation. Sci Transl Med (2015) 1.04
Acute humoral rejection in hepatitis C-infected renal transplant recipients receiving antiviral therapy. Am J Transplant (2003) 1.03
Inferior kidney allograft outcomes in patients with de novo donor-specific antibodies are due to acute rejection episodes. Transplantation (2011) 1.02
Rabbit antithymocyte globulin induction therapy in adult renal transplantation. Pharmacotherapy (2006) 1.02
Effect on kidney graft survival of reducing or discontinuing maintenance immunosuppression after the first year posttransplant. Transplantation (2008) 1.00
Alloantibody and autoantibody monitoring predicts islet transplantation outcome in human type 1 diabetes. Diabetes (2012) 0.99
B-cell depletion in SLE: clinical and trial experience with rituximab and ocrelizumab and implications for study design. Arthritis Res Ther (2013) 0.99
Immune responsiveness in renal transplant recipients: mycophenolic acid severely depresses humoral immunity in vivo. Kidney Int (2002) 0.98
Investigation of lymphocyte depletion and repopulation using alemtuzumab (Campath-1H) in cynomolgus monkeys. Am J Transplant (2010) 0.98
Preformed and de novo donor specific antibodies in visceral transplantation: long-term outcome with special reference to the liver. Am J Transplant (2012) 0.97
Pre- and posttransplantation allosensitization in heart allograft recipients: major impact of de novo alloantibody production on allograft survival. Hum Immunol (2010) 0.97
Randomized controlled pilot study of B cell-targeted induction therapy in HLA sensitized kidney transplant recipients. Am J Transplant (2013) 0.97
The role of donor-specific HLA alloantibodies in liver transplantation. Am J Transplant (2014) 0.96
New crossmatch technique eliminates interference by humanized and chimeric monoclonal antibodies. Transplant Proc (2005) 0.96
Donor-specific antibodies are associated with antibody-mediated rejection, acute cellular rejection, bronchiolitis obliterans syndrome, and cystic fibrosis after lung transplantation. J Heart Lung Transplant (2013) 0.95
Benefits of rituximab combined with intravenous immunoglobulin for desensitization in kidney transplant recipients. Transplantation (2014) 0.93
CD22 ligation inhibits downstream B cell receptor signaling and Ca(2+) flux upon activation. Arthritis Rheum (2013) 0.93
The effect of low and ultra-low dosages Thymoglobulin on peripheral T, B and NK cells in kidney transplant recipients. Transpl Immunol (2012) 0.93
Everolimus plus early tacrolimus minimization: a phase III, randomized, open-label, multicentre trial in renal transplantation. Transpl Int (2012) 0.92
Rapid reduction in donor-specific anti-human leukocyte antigen antibodies and reversal of antibody-mediated rejection with bortezomib in pediatric heart transplant patients. Transplantation (2012) 0.92
Detection of antibodies against HLA-C epitopes in patients with rejected kidney transplants. Transpl Immunol (2010) 0.92
Class II alloantibody and mortality in simultaneous liver-kidney transplantation. Am J Transplant (2013) 0.92
The influence of immuosuppressive therapy on the development of CD4+CD25+ T cells after renal transplantation. Transplant Proc (2007) 0.92
Correlation between human leukocyte antigen antibody production and serum creatinine in patients receiving sirolimus monotherapy after Campath-1H induction. Transplantation (2004) 0.92
Rationale of anti-CD19 immunotherapy: an option to target autoreactive plasma cells in autoimmunity. Arthritis Res Ther (2012) 0.91
Natural history of proteinuria in renal transplant recipients developing de novo human leukocyte antigen antibodies. Transplantation (2011) 0.91
Reduction of alloantibodies via proteasome inhibition in cardiac transplantation. J Heart Lung Transplant (2011) 0.90
De novo donor-specific HLA antibodies are associated with early and high-grade bronchiolitis obliterans syndrome and death after lung transplantation. J Heart Lung Transplant (2014) 0.90
Early versus late acute antibody-mediated rejection in renal transplant recipients. Transplantation (2013) 0.89
A randomized, double-blind, placebo-controlled study of single dose rituximab as induction in renal transplantation: a 3-year follow-up. Transplantation (2012) 0.89
Comprehensive assessment and standardization of solid phase multiplex-bead arrays for the detection of antibodies to HLA-drilling down on key sources of variation. Am J Transplant (2013) 0.89
De novo donor HLA-specific antibodies predict development of bronchiolitis obliterans syndrome after lung transplantation. J Heart Lung Transplant (2014) 0.89
Prevalence, incidence and risk factors for donor-specific anti-HLA antibodies in maintenance liver transplant patients. Am J Transplant (2014) 0.88
Complement-binding anti-HLA antibodies and kidney-allograft survival. N Engl J Med (2013) 6.31
Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. J Heart Lung Transplant (2005) 5.87
Nephrogenic systemic fibrosis: risk factors and incidence estimation. Radiology (2007) 4.25
Tolerogenic immunosuppression for organ transplantation. Lancet (2003) 4.09
Revision of the 1996 working formulation for the standardization of nomenclature in the diagnosis of lung rejection. J Heart Lung Transplant (2007) 3.90
Tumor-induced tolerance and immune suppression depend on the C/EBPbeta transcription factor. Immunity (2010) 3.88
A randomized trial of inhaled cyclosporine in lung-transplant recipients. N Engl J Med (2006) 3.16
Consensus guidelines on the testing and clinical management issues associated with HLA and non-HLA antibodies in transplantation. Transplantation (2013) 2.55
Clinical trial of islet xenotransplantation in Mexico. Xenotransplantation (2006) 2.51
The kSORT assay to detect renal transplant patients at high risk for acute rejection: results of the multicenter AART study. PLoS Med (2014) 2.38
Fatal transfusion-associated graft-versus-host disease in an immunocompetent recipient of a volunteer unit of red cells. Transfusion (2006) 2.26
Assessing relative risks of infection and rejection: a meta-analysis using an immune function assay. Transplantation (2006) 2.24
Serum β2-microglobulin at discharge predicts mortality and graft loss following kidney transplantation. Kidney Int (2013) 2.12
National conference to assess antibody-mediated rejection in solid organ transplantation. Am J Transplant (2004) 2.01
Human amniotic fluid-derived stem cells are rejected after transplantation in the myocardium of normal, ischemic, immuno-suppressed or immuno-deficient rat. J Mol Cell Cardiol (2006) 1.99
Kidney transplantation under minimal immunosuppression after pretransplant lymphoid depletion with Thymoglobulin or Campath. J Am Coll Surg (2005) 1.93
Serial versus isolated assessment of clinical and instrumental parameters in heart failure: prognostic and therapeutic implications. Am Heart J (2003) 1.93
Alemtuzumab preconditioning with tacrolimus monotherapy-the impact of serial monitoring for donor-specific antibody. Transplantation (2008) 1.62
Immune cell function testing: an adjunct to therapeutic drug monitoring in transplant patient management. Clin Transplant (2003) 1.58
Kidney transplantation under a tolerogenic regimen of recipient pretreatment and low-dose postoperative immunosuppression with subsequent weaning. Ann Surg (2003) 1.52
C1q Binding Activity of De Novo Donor-specific HLA Antibodies in Renal Transplant Recipients With and Without Antibody-mediated Rejection. Transplantation (2015) 1.50
Tubular expression of heat-shock protein 27 inhibits fibrogenesis in obstructive nephropathy. Kidney Int (2012) 1.50
Low serum magnesium is associated with decreased graft survival in patients with chronic cyclosporin nephrotoxicity. Nephrol Dial Transplant (2005) 1.48
Host-derived circulating cells do not significantly contribute to cardiac regeneration in heterotopic rat heart transplants. Cardiovasc Res (2005) 1.48
Acute antibody-mediated rejection of cardiac transplants. J Heart Lung Transplant (2006) 1.48
Heterotopic cardiac xenotransplantation in rodents: report of a refined technique in a hamster-to-rat model. Microsurgery (2005) 1.47
T-cell immunity to subclinical cytomegalovirus infection reduces cardiac allograft disease. Circulation (2006) 1.46
HLA-specific antibodies are risk factors for lymphocytic bronchiolitis and chronic lung allograft dysfunction. Am J Transplant (2005) 1.46
Ischemic injury activates PTHrP and PTH1R expression in human ventricular cardiomyocytes. Basic Res Cardiol (2009) 1.45
Use of alemtuzumab and tacrolimus monotherapy for cadaveric liver transplantation: with particular reference to hepatitis C virus. Transplantation (2004) 1.43
Report from a consensus conference on antibody-mediated rejection in heart transplantation. J Heart Lung Transplant (2011) 1.40
[Extracorporeal membrane oxygenation for the treatment of refractory cardiogenic shock in adults: strategies, results, and predictors of mortality]. G Ital Cardiol (Rome) (2014) 1.39
Upper-extremity transplantation using a cell-based protocol to minimize immunosuppression. Ann Surg (2013) 1.30
Survival in allosensitized children after listing for cardiac transplantation. J Heart Lung Transplant (2007) 1.30
Statin use is associated with improved function and survival of lung allografts. Am J Respir Crit Care Med (2003) 1.28
Tacrolimus dosing in pediatric heart transplant patients is related to CYP3A5 and MDR1 gene polymorphisms. Am J Transplant (2003) 1.28
HLA-specific antibodies are associated with high-grade and persistent-recurrent lung allograft acute rejection. J Heart Lung Transplant (2004) 1.27
Assessment of acute renal transplant rejection with blood oxygen level-dependent MR imaging: initial experience. Radiology (2005) 1.27
Disparate distribution of 16 candidate single nucleotide polymorphisms among racial and ethnic groups of pediatric heart transplant patients. Transplantation (2006) 1.24
Five hundred intestinal and multivisceral transplantations at a single center: major advances with new challenges. Ann Surg (2009) 1.21
Dendritic cell subset ratio in peripheral blood correlates with successful withdrawal of immunosuppression in liver transplant patients. Am J Transplant (2003) 1.21
Prognostic implications of serial assessments of pulmonary hypertension in severe chronic heart failure. J Heart Lung Transplant (2006) 1.21
Arterial spin labeling MRI for assessment of perfusion in native and transplanted kidneys. Magn Reson Imaging (2010) 1.17
Cytokine gene polymorphisms moderate illness severity in infants with respiratory syncytial virus infection. Hum Immunol (2003) 1.17
Immunogenicity and immunomodulatory effects of amnion-derived multipotent progenitor cells. Hum Immunol (2008) 1.16
The 2016 International Society for Heart Lung Transplantation listing criteria for heart transplantation: A 10-year update. J Heart Lung Transplant (2016) 1.16
Epithelial-to-mesenchymal transition and chronic allograft tubulointerstitial fibrosis. Transplant Rev (Orlando) (2008) 1.15
Heat shock protein 27 (HSP27): biomarker of disease and therapeutic target. Fibrogenesis Tissue Repair (2012) 1.13
Anti-HLA antibody analysis and crossmatching in heart and lung transplantation. Transpl Immunol (2004) 1.12
HSP27 is involved in the pathogenesis of kidney tubulointerstitial fibrosis. Am J Physiol Renal Physiol (2008) 1.11
Dendritic cell subset ratio in tolerant, weaning and non-tolerant liver recipients is not affected by extent of immunosuppression. Am J Transplant (2005) 1.09
Interleukin-6 promoter -174 polymorphism and spontaneous preterm birth. Am J Obstet Gynecol (2003) 1.08
Blood oxygen level-dependent and perfusion magnetic resonance imaging: detecting differences in oxygen bioavailability and blood flow in transplanted kidneys. Magn Reson Imaging (2009) 1.06
Medical care of kidney transplant recipients after the first posttransplant year. Clin J Am Soc Nephrol (2006) 1.05
Carbon monoxide improves cardiac energetics and safeguards the heart during reperfusion after cardiopulmonary bypass in pigs. FASEB J (2004) 1.04
Adult-onset calorie restriction delays the accumulation of mitochondrial enzyme abnormalities in aging rat kidney tubular epithelial cells. Am J Physiol Renal Physiol (2007) 1.03
Genetic polymorphisms impact the risk of acute rejection in pediatric heart transplantation: a multi-institutional study. Transplantation (2008) 1.03
Leukocyte capture and modulation of cell-mediated immunity during human sepsis: an ex vivo study. Crit Care (2013) 1.03
Cardiac interstitial cells express GATA4 and control dedifferentiation and cell cycle re-entry of adult cardiomyocytes. J Mol Cell Cardiol (2008) 1.03
Tacrolimus dosing in adult lung transplant patients is related to cytochrome P4503A5 gene polymorphism. J Clin Pharmacol (2004) 1.02
Allosensitized humans are at no greater risk of humoral rejection of GT-KO pig organs than other humans. Xenotransplantation (2006) 1.02
The HLA class II Allele DRB1*1501 is over-represented in patients with idiopathic pulmonary fibrosis. PLoS One (2011) 1.02
Native kidney function following liver transplantation using calcineurin inhibitors: single-center analysis with 20 years of follow-up. Clin Transplant (2013) 1.02
Experience with immune monitoring in lung transplant recipients: correlation of low immune function with infection. Transplantation (2009) 1.01
Long-term effects of alemtuzumab on regulatory and memory T-cell subsets in kidney transplantation. Transplantation (2012) 1.01
Antibody-mediated rejection: treatment alternatives and outcomes. Transplant Rev (Orlando) (2009) 1.00
Enhanced donor-specific alloreactivity occurs independently of immunosuppression in children with early liver rejection. Am J Transplant (2005) 1.00
Anti-HLA alloantibodies in pediatric solid organ transplantation. Pediatr Transplant (2006) 1.00
HLA mismatching increases the risk of BK virus nephropathy in renal transplant recipients. Am J Transplant (2004) 0.99
Retransplant candidates have donor-specific antibodies that react with structurally defined HLA-DR,DQ,DP epitopes. Transpl Immunol (2007) 0.99
Persistent donor-specific alloreactivity may portend delayed liver rejection during drug minimization in children. Front Biosci (2007) 0.98
In vitro and in vivo cardiomyogenic differentiation of amniotic fluid stem cells. Stem Cell Rev (2011) 0.97
Report from a consensus conference on the sensitized patient awaiting heart transplantation. J Heart Lung Transplant (2009) 0.97
Long-term IgG response to porcine Neu5Gc antigens without transmission of PERV in burn patients treated with porcine skin xenografts. J Immunol (2013) 0.96
Evolution of the immunosuppressive strategies for the intestinal and multivisceral recipients with special reference to allograft immunity and achievement of partial tolerance. Transpl Int (2008) 0.96
Bisphosphonates and bone fractures in long-term kidney transplant recipients. Transplantation (2008) 0.96
Renal function and genetic polymorphisms in pediatric heart transplant recipients. J Heart Lung Transplant (2012) 0.96
Tumor necrosis factor-alpha promoter gene polymorphism -308 and chorioamnionitis. Obstet Gynecol (2003) 0.95
Measurements of global cell-mediated immunity in renal transplant recipients with BK virus reactivation. Am J Clin Pathol (2008) 0.95
Detection of CD8+ T cells sensitized to BK virus large T antigen in healthy volunteers and kidney transplant recipients. Hum Immunol (2006) 0.95
Comparing kidney perfusion using noncontrast arterial spin labeling MRI and microsphere methods in an interventional swine model. Invest Radiol (2011) 0.95
Structural aspects of HLA class I epitopes reacting with human monoclonal antibodies in Ig-binding, C1q-binding and lymphocytotoxicity assays. Hum Immunol (2013) 0.95
Functional characteristics of lymphocytes propagated from a human multivisceral allograft. Clin Transplant (1990) 0.94
Intracerebral xenotransplantation: recent findings and perspectives for local immunosuppression. Curr Opin Organ Transplant (2011) 0.94
Genetic polymorphisms influence mycophenolate mofetil-related adverse events in pediatric heart transplant patients. J Heart Lung Transplant (2010) 0.94
Incidence of hyperacute rejection in pig-to-primate transplantation using organs from hDAF-transgenic donors. Transplantation (2002) 0.93
Quantitative MR measures of intrarenal perfusion in the assessment of transplanted kidneys: initial experience. Acad Radiol (2009) 0.93
Humoral immunity and antibody-mediated rejection in solid organ transplantation. Semin Immunol (2011) 0.92
Cytokine profiles in a rat model of otitis media with effusion caused by eustachian tube obstruction with and without Streptococcus pneumoniae infection. Laryngoscope (2002) 0.92
The International Xenotransplantation Association consensus statement on conditions for undertaking clinical trials of porcine islet products in type 1 diabetes-- executive summary. Xenotransplantation (2009) 0.92
Update and review: state-of-the-art management of cytomegalovirus infection and disease following thoracic organ transplantation. Transplant Proc (2011) 0.91
CKD stage-to-stage progression in native and transplant kidney disease. Nephrol Dial Transplant (2007) 0.90
Fibrogenesis in kidney transplantation: potential targets for prevention and therapy. Transplantation (2009) 0.90
Ureteral stenosis in HDAF pig-to-primate renal xenotransplantation: a phenomenon related to immunological events? Am J Transplant (2004) 0.90
Measurement and comparison of T1 relaxation times in native and transplanted kidney cortex and medulla. J Magn Reson Imaging (2011) 0.89
Plasma inflammatory mediators associated with bone metabolism in COPD. COPD (2010) 0.89